# Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients

> **NCT04364035** · PHASE2 · COMPLETED · sponsor: **Aelix Therapeutics** · enrollment: 50 (actual)

## Conditions studied

- HIV/AIDS

## Interventions

- **BIOLOGICAL:** ChAdOx1.HTI
- **BIOLOGICAL:** MVA.HTI
- **DRUG:** GS-9620
- **BIOLOGICAL:** Placebo
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT04364035
- **Lead sponsor:** Aelix Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-20
- **Primary completion:** 2022-10-03
- **Final completion:** 2022-12-16
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04364035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04364035, "Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04364035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*